Could a common diabetes drug save sight in glaucoma patients?
NCT ID NCT05426044
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether metformin, a drug used for diabetes, can protect the optic nerve and slow vision loss in people with glaucoma. 125 participants with worsening glaucoma will take either metformin or a placebo for 24 months. The goal is to see if metformin can slow the thinning of the nerve layer in the eye and preserve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Metformin
- What this could lead to
- If successful, this could show that metformin, a common diabetes drug, can protect the optic nerve and slow vision loss in glaucoma patients.
- What could go wrong
- This is a phase 2 trial with only 125 people, so results may not apply to everyone. It's also possible that metformin won't slow vision loss more than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HKU Eye Centre
RECRUITINGWong Chuk Hang, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bangkok community eye check reveal hidden glaucoma risks?
- AI eye exam: a new hope for early glaucoma detection?
- Can a tiny eye implant replace glaucoma drops?
- Can a new tube implant surgery outperform standard glaucoma surgery?
- Could your personality predict glaucoma drug side effects?
- Could a single eye implant replace years of glaucoma drops?